Tele: 561.316.3330
Breaking Medical Device News

Thursday, October 21, 2021

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR
HomeCook Medical Brings Hemospray™ to U.S. Physicians to Treat Gastrointestinal Bleeds

Cook Medical Brings Hemospray™ to U.S. Physicians to Treat Gastrointestinal Bleeds

The FDA has granted Cook Medical approval to market Hemospray in the United States. An endoscopic hemostat, Hemospray achieves hemostasis with a proprietary inorganic powder.

Bleeding in the gastrointestinal tract is a leading cause of morbidity and is associated with an estimated 20,000 deaths per year in the United States alone.1 Since 2011, Cook Medical’s Hemospray has been used to treat bleeding in the GI tract, with thousands of patients treated throughout Europe, Canada and other countries around the globe.

“We are extremely pleased to receive this approval to market from FDA,” said Barry Slowey, president of Cook Winston-Salem and vice president of Cook Medical’s Endoscopy specialty. “We have worked diligently to bring a different approach to hemostasis for gastroenterology teams across the United States.”

Hemospray will soon be available to clinicians across the U.S. for the treatment of non-variceal GI bleeds. This product is a single-use device that delivers hemostatic powder through the channel of an endoscope toward the source of a bleed. When the powder comes in contact with blood, it absorbs water and forms a gel, which acts cohesively and adhesively to create a stable mechanical barrier that covers the bleeding site. Hemospray is a nonthermal, nontraumatic treatment modality for achieving hemostasis.

“Hemospray gives clinicians another tool for the care of their patients,” said DJ Sirota, vice president of Cook Medical’s MedSurg division. “Patients have been our number one priority for over 50 years and we’ve worked hard to bring this innovation to the field of gastroenterology across the U.S.“

Numerous reports in the clinical literature have demonstrated the clinical utility of Hemospray when used alone or with other methods.2 In a summary of 19 studies of Hemospray comprising treatment of 234 patients, the combined rate of successful hemostasis was 88.5 percent. Rebleeding occurred within 72 hours in 16.2% after successful initial hemostasis with Hemospray.

Current endoscopic hemostasis treatment options can be challenging. Thermal, mechanical or contact devices can carry a risk of further tissue damage and require precise placement of the device directly onto the bleeding vessel.3 Hemospray represents a different approach to treat GI bleeds by helping to achieve hemostasis without the precision or direct visualization required of other current treatments.3 This makes Hemospray a treatment option for bleeding from damaged tissue where the bleeding source cannot be easily identified.


Reference

1 El-Tawil A., Trends on gastrointestinal bleeding and mortality: Where are we standing?, World J Gastroenterol, 2012. 18: 1154-58

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Contraline Closes $10.7 Million Series A Financing to Become a Clinical Stage Company

This infusion of capital will support the initiation of a first-in-human trial of ADAM™, the world’s first hydrogel implant designed to provide long-lasting, non-permanent contraception for men.

Adam S. Epstein New CEO of AliMed, Inc.

In his prior role as Chief Commercial Officer, Epstein directed all customer-facing, demand generation and product development activities. Under his new leadership, AliMed will continue to build a robust portfolio of contracted positions with major, national GPO’s, IDN’s, and Distribution partners to drive sales growth.

Tony Collins Appointed CFO of Xenter

“Xenter is building a platform for medical innovations that is transformational. The only way we can achieve our objectives is if we have great leaders like Tony Collins leading our company,” stated Richard J. Linder, Founder, Chairman & CEO of Xenter, Inc. “Tony brings incredible depth and experience to his new role as Chief Financial Officer.

Scott Sexton Appointed President at FIGUR8

"Scott brings to FIGUR8 30 years of workers' compensation, casualty, disability, and commercial health experience, most recently serving as a market leader for CorVel's national carrier practice sales team," said Nan-Wei Gong, CEO, and co-founder of FIGUR8.

Insulet Announces Board of Director Changes with Appointment of Luciana Borio, M.D. and Retirement of Sally W. Crawford

Luciana Borio MD is a respected physician with vast experience in advancing major regulatory and policy agendas for the United States.

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

By using this website you agree to accept Medical Device News Magazine Privacy Policy